Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers

被引:0
|
作者
Z Kote-Jarai
A Salmon
T Mengitsu
M Copeland
A Ardern-Jones
I Locke
S Shanley
B Summersgill
Y-J Lu
J Shipley
R Eeles
机构
[1] Translational Cancer Genetics Team,
[2] The Institute of Cancer Research,undefined
[3] Sharett Institute of Oncology,undefined
[4] Hadassah University Medical Center,undefined
[5] Royal Marsden NHS Foundation Trust,undefined
[6] Molecular Cytogenetics,undefined
[7] The Institute of Cancer Research,undefined
来源
British Journal of Cancer | 2006年 / 94卷
关键词
breast cancer; chromosomal damage; irradiation; M-FISH;
D O I
暂无
中图分类号
学科分类号
摘要
Deleterious mutations in the BRCA1 gene predispose women to an increased risk of breast and ovarian cancer. Many functional studies have suggested that BRCA1 has a role in DNA damage repair and failure in the DNA damage response pathway often leads to the accumulation of chromosomal aberrations. Here, we have compared normal lymphocytes with those heterozygous for a BRCA1 mutation. Short-term cultures were irradiated (8Gy) using a high dose rate and subsequently metaphases were analysed by 24-colour chromosome painting (M-FISH). We scored the chromosomal rearrangements in the metaphases from five BRCA1 mutation carriers and from five noncarrier control samples 6 days after irradiation. A significantly higher level of chromosomal damage was detected in the lymphocytes heterozygous for BRCA1 mutations compared with normal controls; the average number of aberrations per mitosis was 3.48 compared with 1.62 in controls (P=0.0001). This provides new evidence that heterozygous mutation carriers have a different response to DNA damage compared with noncarriers and that BRCA1 has a role in DNA damage surveillance. Our finding has implications for treatment and screening of BRCA1 mutation carriers using modalities that involve irradiation.
引用
收藏
页码:308 / 310
页数:2
相关论文
共 50 条
  • [21] Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
    Rebbeck, TR
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S15 - S17
  • [22] Clinical management of BRCA1 and BRCA2 mutation carriers
    Domchek, S. M.
    Weber, B. L.
    ONCOGENE, 2006, 25 (43) : 5825 - 5831
  • [23] The clinical management of BRCA1 and BRCA2 mutation carriers
    Anthony P. Gulati
    Susan M. Domchek
    Current Oncology Reports, 2008, 10 : 47 - 53
  • [24] The Clinical Management of BRCA1 and BRCA2 Mutation Carriers
    Gulati, Anthony P.
    Domchek, Susan M.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (01) : 47 - 53
  • [25] Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers
    Gast K.C.
    Viscuse P.V.
    Nowsheen S.
    Haddad T.C.
    Mutter R.W.
    Wahner Hendrickson A.E.
    Couch F.J.
    Ruddy K.J.
    Current Treatment Options in Cardiovascular Medicine, 2018, 20 (2)
  • [26] Survival and recurrence after breast cancer in BRCA1/2 mutation carriers
    El-Tamer, M
    Russo, D
    Troxel, A
    Bernardino, LP
    Mazziotta, R
    Estabrook, A
    Ditkoff, BA
    Schnabel, F
    Mansukhani, M
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : 157 - 164
  • [27] Clinical management of BRCA1 and BRCA2 mutation carriers
    Domchek, SM
    Armstrong, K
    Weber, BL
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 2 - 3
  • [28] Adrenal tumors in BRCA1/BRCA2 mutation carriers
    Barak, F
    Shiri-Svredlov, R
    Sade, RBB
    Kruglikova, A
    Friedman, E
    Ben-Dor, D
    Goldberg, I
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2001, 98 (03): : 277 - 279
  • [29] Clinical management of BRCA1 and BRCA2 mutation carriers
    S M Domchek
    B L Weber
    Oncogene, 2006, 25 : 5825 - 5831
  • [30] Chemoprevention options for BRCA1 and BRCA2 mutation carriers
    Eeles, RA
    Powles, TJ
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 93S - 99S